From a historical perspective, selective α7 nAChR agonists have been targeted for cognitive deficits associated with schizophrenia (for recent reviews see [151, 152, 226]) and dementia in Alzheimer’s disease [227, 228]. Here, CHRNA7 is linked to early-onset autosomal dominant Alzheimer disease.